about
Immunotherapy for primary brain tumors: no longer a matter of privilegeTrial Watch-Oncolytic viruses and cancer therapyMesenchymal stem cells genetically modified by lentivirus-mediated interleukin-12 inhibit malignant ascites in mice.Artificially designed pathogens - a diagnostic option for future military deploymentsAdvances in immunotherapy for the treatment of glioblastoma.Brain Cancer Stem Cells in Adults and Children: Cell Biology and Therapeutic Implications.Comparative proteomics as a tool for identifying specific alterations within interferon response pathways in human glioblastoma multiforme cells.
P2860
Q27002510-1A77C343-0C81-44ED-98D7-86FD7CEE733FQ28072347-FE7AC061-5A7A-4B5C-8AFE-1EACDF003D03Q34119602-61D4A189-F861-4083-B66D-0847E73D2124Q35830879-89CE7DB0-8AA3-4E1D-95AF-4D590DAD0552Q38981383-2091A34B-B1DC-4949-AD8E-F352358FFF41Q39218100-61ABA2D7-ECEE-4277-A0D1-2E8FC7318805Q50128059-E28E7CA1-E9E3-4F44-86FC-B9DBE0C3C90C
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Immunovirotherapy for the treatment of glioblastoma.
@en
type
label
Immunovirotherapy for the treatment of glioblastoma.
@en
prefLabel
Immunovirotherapy for the treatment of glioblastoma.
@en
P2093
P2860
P356
P1433
P1476
Immunovirotherapy for the treatment of glioblastoma
@en
P2093
Jianfang Ning
Peter E Fecci
Tooba A Cheema
P2860
P304
P356
10.4161/ONCI.27218
P577
2014-01-01T00:00:00Z